Journal
LEUKEMIA & LYMPHOMA
Volume 60, Issue 11, Pages 2771-2778Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2019.1599110
Keywords
Acute myeloid leukemia; consolidation chemotherapy; anthracycline; cytarabine; immunotherapy; cytotoxic T cells
Categories
Funding
- Swedish Research Council
- Swedish Cancer Foundation [CAN 2016/351]
Ask authors/readers for more resources
Consolidation chemotherapy in acute myeloid leukemia (AML) aims at eradicating residual leukemic cells and mostly comprises high-dose cytarabine with or without the addition of anthracyclines, including daunorubicin. Immunogenic cell death (ICD) may contribute to the efficacy of anthracyclines in solid cancer, but the impact of ICD in AML is only partly explored. We assessed aspects of ICD, as reflected by calreticulin expression, in primary human AML blasts and observed induction of surface calreticulin upon exposure to daunorubicin but not to cytarabine. We next assessed immune phenotypes in AML patients in complete remission (CR), following consolidation chemotherapy with or without anthracyclines. These patients subsequently received immunotherapy with histamine dihydrochloride (HDC) and IL-2. Patients who had received anthracyclines for consolidation showed enhanced frequencies of CD8(+) T-EM cells in blood along with improved survival. We propose that the choice of consolidation therapy prior to AML immunotherapy may determine clinical outcome.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available